Long-term treatment results of Polish pediatric and adolescent patients enrolled in the ALL IC-BFM 2002 trial
Language English Country United States Media print-electronic
Document type Clinical Trial, Letter, Multicenter Study, Research Support, Non-U.S. Gov't
Grant support
STRATEGMED3/304586/5/NCBR/2017
National Centre for Research and Development, Poland - International
PubMed
31432528
PubMed Central
PMC6852109
DOI
10.1002/ajh.25619
Knihovny.cz E-resources
- MeSH
- Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy genetics mortality pathology MeSH
- Cell Lineage MeSH
- Chromosome Aberrations MeSH
- Child MeSH
- Immunophenotyping MeSH
- Kaplan-Meier Estimate MeSH
- Infant MeSH
- Humans MeSH
- Adolescent MeSH
- Prednisone administration & dosage MeSH
- Child, Preschool MeSH
- Cause of Death MeSH
- Antineoplastic Combined Chemotherapy Protocols therapeutic use MeSH
- Recurrence MeSH
- Risk Factors MeSH
- Treatment Outcome MeSH
- Check Tag
- Child MeSH
- Infant MeSH
- Humans MeSH
- Adolescent MeSH
- Male MeSH
- Child, Preschool MeSH
- Female MeSH
- Publication type
- Letter MeSH
- Clinical Trial MeSH
- Multicenter Study MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Poland epidemiology MeSH
- Names of Substances
- Prednisone MeSH
Department of Applied Psychology Medical University of Lublin Lublin Poland
Department of Hematology and Pediatrics Children's Hospital Warsaw Poland
Department of Pediatric Oncology and Hematology Children's Hospital Kielce Poland
Department of Pediatric Oncology Hematology Medical University of Białystok Białystok Poland
Department of Pediatrics Hematology and Oncology Collegium Medicum of Bydgoszcz Bydgoszcz Poland
Department of Pediatrics Hematology and Oncology Medical University of Szczecin Szczecin Poland
Department of Pediatrics Hematology and Oncology Medical University of Zabrze Zabrze Poland
Department of Pediatrics Oncology Hematology and Diabetology Medical University of Łódź Łódź Poland
See more in PubMed
Stary J, Zimmermann M, Campbell M, et al. Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC‐BFM 2002. J Clin Oncol. 2014;32(3):174‐184. PubMed
Cui L, Li ZG, Chai YH, et al. Outcome of children with newly diagnosed acute lymphoblastic leukemia treated with CCLG‐ALL 2008: The first nation‐wide prospective multicenter study in China. Am J Hematol. 2018;93(7):913‐920. PubMed
Hunger SP, Lu X, Devidas M, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. J Clin Oncol. 2012;30(14):1663‐1669. PubMed PMC
Christensen MS, Heyman M, Mottonen M, et al. Treatment‐related death in childhood acute lymphoblastic leukaemia in the Nordic countries: 1992‐2001. Br J Haematol. 2005;131(1):50‐58. PubMed
Moricke A, Zimmermann M, Valsecchi MG, et al. Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP‐BFM ALL 2000. Blood. 2016;127(17):2101‐2112. PubMed
Moricke A, Reiter A, Zimmermann M, et al. Risk‐adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL‐BFM 95. Blood. 2008;111(9):4477‐4489. PubMed
